Engflag

Fluindione

Quick links to important sections

Fluindione

Fluindione_SK

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Fluindione

Property Description
Active Ingredient Fluindione
Form Oral tablet (film-coated)
Pharmacological Class Vitamin K Antagonist (VKA) / Oral Anticoagulant
General Purpose Prevention of blood clotting (Anticoagulation)
Origin Synthetic (Indanedione derivative)

What Type of Medicine is Fluindione? (Definition and Classification)

Fluindione is a synthetic, single-ingredient medication, available only by prescription, classified as an Oral Anticoagulant. It belongs to the Vitamin K Antagonist (VKA) pharmacological class. The active ingredient, Fluindione (INN), is an indanedione derivative, chemically distinct from the coumarin derivatives that make up most of the VKA class, though sharing the common goal of managing thrombosis risk.

This medication is primarily presented as a tablet (film-coated or scored) for oral ingestion. The indanedione structure of Fluindione is noted in pharmacological studies as a key differentiator within the VKA group.

What is the General Purpose of Fluindione? (High-Level Benefit)

The core purpose of Fluindione is to achieve therapeutic anticoagulation, which means reducing the blood's ability to form clots. This function is accomplished by interfering with the Vitamin K cycle in the liver, a mechanism confirmed in extensive research on the VKA drug class.

By disrupting this essential process, the medication diminishes the liver's ability to produce fully active clotting factors (like Factors II, VII, IX, and X). This controlled reduction in clotting capacity provides the general benefit of sustained protection required for patients undergoing long-term maintenance therapy against the formation of dangerous blood clots.

What is Fluindione Made Of and How is it Taken? (Form and Composition)

Fluindione is composed of the active ingredient, Fluindione, combined with various pharmaceutical excipients—inactive substances required to formulate the product into a stable and reliable tablet. The medication's design for oral ingestion confirms its suitability for long-term administration where consistent, daily intake is necessary to maintain therapeutic levels of reduced clotting capacity.

Regulatory References

  1. NIH StatPearls: Vitamin K

What side effects are possible with Fluindione?

Possible Side Effects and Safety Information: Fluindione

Fluindione is an anticoagulant and its safety profile is defined by a primary risk of bleeding and hemorrhage, which is the most frequent and critical adverse event. Bleeding can range from minor events, such as bruising and nosebleeds, to severe, life-threatening internal or intracranial hemorrhage. The official safety profile requires mandatory monitoring of the International Normalized Ratio (INR) to manage this risk.

Documented Adverse Reactions

Side effects are categorized by frequency and affected organ system as documented in regulatory sources:

  • Primary Risk: Hemorrhage (can be very common, ranging from minor to major).
  • Rare, Serious Reactions: Officially documented rare but clinically significant adverse reactions include Calciphylaxis (a serious vascular calcification disorder) and severe immunoallergic reactions such as DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms) and severe skin necrosis.
  • System-Organ Classes: Reactions affect the blood and lymphatic system (bleeding), skin and subcutaneous tissue (rashes, hypersensitivity), hepatobiliary system (liver enzyme elevation), and renal system (kidney damage).

Safety Restrictions and Vulnerable Populations

Regulatory documentation defines specific restrictions for use:

  • Contraindications: Fluindione is strictly contraindicated during pregnancy and lactation due to the risk of fetal harm, and in cases of severe hepatic impairment.
  • Older Adults: Patients in the older adult population (typically ge 80 years) are considered at a substantially higher risk for adverse events, including bleeding, which often necessitates closer monitoring and potentially lower dosing.
  • Time-Related Pattern: The official safety profile notes that the highest risk for adverse effects, particularly bleeding, is concentrated during the initial weeks and first months of therapy.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information states that the primary manifestation of Fluindione overdose is excessive anticoagulation, which presents clinically as bleeding (hemorrhage). This outcome is directly quantifiable by laboratory evidence of an excessively elevated International Normalized Ratio (INR) or prolonged Prothrombin Time.

Documented overdose presentations range from minor external signs, such as unexplained bruising or persistent gum bleeding, to severe, potentially life-threatening hemorrhagic events. Major bleeding outcomes include gross hematuria (blood in urine), bloody or black stools, and intracranial or gastrointestinal hemorrhage.

Emergency Action Requirements:

Official government guidance mandates that users seek immediate medical attention for any suspected overdose or for the occurrence of severe or recurrent bleeding. Urgent medical help must be sought immediately for any sign of major hemorrhage, such as vomiting blood or sudden, severe headache.

Management procedures officially described involve providing symptomatic and supportive care. The specific reversal agent for excessive anticoagulation is documented as Vitamin K1 (Phytonadione). Throughout the management process, regular INR monitoring is a required procedural step to assess the degree of anticoagulant effect.

Therapeutic Uses of Fluindione

What Fluindione Treats: Main Uses and Benefits

Fluindione is commonly used to help with symptoms related to Deep Vein Thrombosis (DVT), and is relevant in contexts involving the risk of Pulmonary Embolism (PE). The medication may be part of symptomatic management for providing long-term support to address the recurrence of these potentially severe symptomatic episodes. It is generally used as part of supportive, ongoing care for conditions like Atrial Fibrillation, the presence of mechanical heart valves, and other high-risk situations.

The medication supports the therapeutic domain involving the risk of new or enlarged blood clots. This supportive function contributes to maintaining a sense of stability when symptoms are more noticeable, and assists patients with coping more steadily with their condition.

“This medication plays a role in managing a persistent, high-risk factor by providing supportive relief that helps ease the overall symptom load.”

Quick Fact: Relief for Clot Risk

Fluindione is utilized across patient groups, including older adults and those with a history of recurrent clotting, who require continuous, chronic supportive relief to manage their persistent prothrombotic risk. This consistent therapeutic coverage is applied to help with symptoms related to acute or disruptive episodes.

Regulatory References

  1. French Public Database of Medicines

Eligibility and Restrictions for Use

Who can and cannot use Fluindione?

The official regulatory profile for Fluindione strictly defines patient eligibility through absolute contraindications and population restrictions.

Populations for Whom Use is Established

Use is established in adults (typically ge 18 years) requiring oral anticoagulation for approved conditions. Older adults are a commonly treated population, though regulatory guidance notes they may require careful monitoring due to potential increased sensitivity to the effects of Vitamin K Antagonists.

Populations for Whom Use is Contraindicated

Fluindione is contraindicated and must not be used in several patient groups, including those with a known hypersensitivity or allergy to the drug's components. Use is strictly prohibited in cases of severe hepatic impairment (severe liver dysfunction). Furthermore, the medication is contraindicated throughout pregnancy and lactation. Eligibility is also precluded by concurrent use with specific agents, such as high doses of aspirin, phenylbutazone, miconazole (non-cutaneous), or St. John's wort.

Age-Related Restrictions

The medication is generally not established or not recommended for the pediatric population (children and adolescents) due to insufficient data in regulatory summaries for this age group.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Fluindione, an oral anticoagulant, has a documented interaction profile focused on altering its effect on blood clotting, as defined in government regulatory information.

Contraindicated Combinations

Certain combinations are formally prohibited due to a high risk of adverse events. These contraindicated substances include high-dose Acetylsalicylic acid (Aspirin), Phenylbutazone, and the antifungal agent Miconazole (excluding topical forms). The herbal product St. John’s Wort is also formally listed as a contraindicated co-administration.

Clinically Significant Interactions

Interaction classifications are structured to note agents that alter Fluindione's activity via different mechanisms:

  • Pharmacodynamic Reinforcement: Co-administration with other antithrombotic agents (e.g., Alteplase) or certain supplements like Glucosamine may lead to additive effects, increasing the risk of bleeding.
  • Exposure Alteration: Certain medicinal products can modify the amount of Fluindione in the bloodstream. For instance, Apalutamide is associated with decreased Fluindione serum concentration, while Asciminib is associated with increased concentration.
  • Metabolic Influence: Substances like Enzalutamide have documented enzyme-inducing effects that may influence Fluindione's metabolism.

Dietary and Population Constraints

Inconsistent intake of Vitamin K-rich foods (such as broccoli, spinach, or liver) is documented to influence Fluindione's activity. A high intake may antagonize the anticoagulant effect, while a low intake may enhance it. Furthermore, the presence of severe hepatic impairment is a population-specific contraindication, reflecting a heightened interaction and adverse risk profile.

Mechanism of Action

How Fluindione Works

Fluindione's action is defined by its specific interference with the body's natural coagulation process at the level of protein synthesis in the liver.

Selective Inhibition of the Vitamin K Recycling Pathway

Fluindione's mechanism centers on the enzyme Vitamin K Epoxide Reductase Complex 1 (VKORC1), which it inhibits competitively. This molecular interference prevents the recycling of oxidized Vitamin K back into its active form ( KH2). This action depletes the KH2 cofactor necessary for creating functional clotting proteins.

Impairment of Coagulation Factor Activation

The resulting scarcity of active KH2 leads to the functional impairment of gamma-Glutamyl Carboxylase, preventing the necessary post-translational modification of new coagulation factor precursors (Factors II, VII, IX, X). The liver then secretes inactive precursors, leading to a systemic reduction in the overall capacity for the blood to form fibrin clots.

Time-Dependent Modulation of Systemic Hemostasis

The full physiological effect is not immediate but emerges gradually over several days. This time-dependent modulation is a consequence of the mechanism's reliance on the natural clearance rate of the pre-existing, active clotting factors already circulating in the bloodstream, which results in a time-dependent, sustained change in the hemostatic balance.

Dosage and Administration Information

How Fluindione is Used: Official Administration Guidelines

Fluindione is an Oral Anticoagulant whose use is governed by official prescribing instructions intended to support therapeutic effectiveness and patient safety. Its administration is characterized by a reliance on continuous clinical monitoring.

Administration and Dosing Schedule

Feature Official Labeled Guideline
Route of Administration The medication is approved exclusively for oral ingestion (swallowed by mouth).
Initial (Loading) Dose A typical initiation regimen is 20 mg taken once daily for approximately three consecutive days.
Maintenance Dose Highly variable and individualized, generally ranging from 5 mg to 40 mg daily, as determined by laboratory results.
Frequency Doses are administered once daily (o.d.), often recommended to be taken at a consistent time.

Key Procedural Requirements

Fluindione therapy requires a dynamic approach to dosing, dictated by a specific blood test:

  • Dose Adjustment: The final daily dose is not fixed and is adjusted using International Normalized Ratio (INR) test results. The 20 mg tablet is scored to allow for flexible adjustments in 5 mg increments (quarter steps).
  • Monitoring Constraint: Dose decisions and adjustments are required to be guided by regular monitoring of the patient's INR to maintain the specific target therapeutic range.
  • Population Specifics: Older adults may require special consideration and individualized dosing due to the high variability in dose requirements observed in this population.

The overall official protocol establishes Fluindione as a long-term/chronic treatment requiring initial rapid dosing followed by continuous, daily adjustment based on laboratory parameters, which involves constant clinical oversight.

Recent Clinical Evidence

Fluindione is a Vitamin K Antagonist (VKA) studied in populations with thromboembolic risk associated with Atrial Fibrillation (AF). Research primarily utilizes Randomized Controlled Trials (RCTs) and Systematic Reviews focused on high-risk and older adult populations. Studies monitor outcomes like stroke and systemic embolism. The VKA class is a long-standing comparison point in research; however, dedicated, large-scale, contemporary Fluindione-specific RCTs are limited, and evidence often involves reviews that group it with other similar medications.

Fluindione was also studied for use in patients who have experienced Venous Thromboembolism (VTE) (Deep Vein Thrombosis and Pulmonary Embolism) who were studied for continued use to monitor the risk of clot recurrence. Evidence contributes to understanding the long-standing use of the VKA class for VTE, though the strongest evidence is often centered on other VKAs.

For patients with Mechanical Heart Valves, Fluindione was evaluated in Older Randomized Trials and Long-term Observational Studies that monitored major thromboembolism events. The VKA class represents a long-standing pharmacological approach for managing the risk associated with these devices.

In general, the research landscape highlights several uncertainties: Follow-up durations were limited in some trials, meaning long-term effects are not fully established by specific Fluindione data. Comparative evidence is lacking against newer anticoagulant treatments, and data for certain groups (such as pediatric or pregnant populations) remain insufficient. The evidence quality varies across studies, and some foundational trials are older.

Key Studies & References

  1. Vitamin K Antagonists (VKA) - StatPearls
  2. Management of Antithrombotic Therapy in Patients with Mechanical Heart Valves: A Narrative Review

Frequently Asked Questions (FAQ)

Common questions about Fluindione (FAQ)

Q: What is Fluindione used to treat? (Which conditions does it manage?)

A: According to official product information and clinical studies, Fluindione is an oral anticoagulant primarily used to manage and prevent blood clots. It is indicated for thromboembolic disorders such as Venous Thrombosis (DVT), Pulmonary Embolism (PE), and in patients with conditions like Atrial Fibrillation who require long-term anticoagulation.

Q: How quickly does Fluindione start working?

A: Studies on this class of medication show that the full effect of Fluindione is not immediate. Its mechanism depends on the body clearing existing clotting factors, which takes time. The targeted therapeutic effect, measured by the International Normalized Ratio (INR), typically emerges gradually over a period of several days after starting the initial doses.

Q: Are there any dietary restrictions when taking Fluindione?

A: Official information documents the importance of a consistent and balanced intake of Vitamin K-rich foods, such as green leafy vegetables. Sudden or large changes in the consumption of these foods are generally discouraged because they can alter the effectiveness of Fluindione and potentially impact the stability of the blood thinning level.

Q: What should I do if I miss a dose of Fluindione?

A: When a dose is missed, regulatory patient leaflets typically outline a standard procedure, such as taking the dose if remembered on the same day or skipping it if it is nearly time for the next dose. Never take a double dose to compensate for a missed one. Any specific instructions related to a patient’s regimen should be confirmed with the treating healthcare professional.

Q: Can I stop taking Fluindione once my condition improves?

A: Fluindione is designated for long-term or chronic treatment to ensure continuous protection against dangerous blood clots. Official documentation states that discontinuation must only be carried out under the direct supervision of a healthcare provider. The official protocol notes that abrupt cessation without clinical oversight is generally not advised.

Q: What should I do if I think I am having a major bleed?

A: Since bleeding is the primary and most serious risk associated with this medication, any sign of severe or uncontrollable bleeding (such as excessive or unusual bruising, or significant blood loss) is considered a medical emergency. In the event of severe bleeding, regulatory documents specify that immediate medical attention or contact with emergency services is required.

How should Fluindione be stored and disposed of?

How to Store and Dispose of Fluindione

The storage and disposal of Fluindione tablets must adhere strictly to official regulatory guidelines to ensure the medicine's stability and safety.

Storage Requirements

Fluindione must be kept out of the sight and reach of children to prevent accidental ingestion. The tablets should be stored at room temperature, typically not exceeding 25°C, in their original container. It is mandatory to protect the medication from light and moisture and to keep it from freezing or exposure to excessive heat. Stability is maintained when the product is stored under these labeled conditions until the printed expiration date; outdated medicine must not be kept.

Official Disposal Instructions

Unused or expired Fluindione must be disposed of according to local regulations. The preferred official method is returning the medicine through an authorized drug take-back program. As Fluindione is not on the FDA's flush list, it must not be flushed down the toilet. If a take-back program is unavailable, the tablets should be mixed with an undesirable substance (like dirt or coffee grounds), sealed, and discarded in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Fluindione found in:

A-Z Index: